A Phase 3 interventional study of LY2189265 and Placebo in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 14 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-05-22.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 21st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 492 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 57th largest by enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2012, is one of 85 in phase 3, and was the 80th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.
Rescue therapy (defined as alternative antihyperglycemic medication use or dose modification of oral antihyperglycemic medication [OAM]) may have been initiated during the planned treatment period if the participant discontinued study drug or met prespecified thresholds for severe, persistent hyperglycemia. Efficacy data, as well as data for hypoglycemic episodes from participants who permanently discontinued study treatment but switched to another diabetes medication and remained in the study, were censored from the point of initiating new treatment onwards.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
Drug: LY2189265
Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
Drug: LY2189265 · Drug: Placebo
Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.
Drug: Liraglutide
Also known as: Dulaglutide
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, prestudy therapy (oral antihyperglycemic medication \[OAM\] yes/no), baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 52 Weeks
LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.
Time frame: Baseline, 52 weeks
Percentage of Participants Who Achieved HbA1c <=6.5% or <7%
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% at Week 26 and Week 52 was analyzed with a Cochran-Mantel-Haenszel test stratified by prestudy therapy (OAM yes/no) and baseline BMI group (\<25 or \>=25 kg/m\^2).
Time frame: Up to 26 and 52 weeks
Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks
LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline FBG as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks, 52 weeks
Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks and 52 Weeks
Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal, and at bedtime. LS means were calculated using analysis of covariance (ANCOVA) model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline SMBG as a covariate.
Time frame: Baseline, 26 weeks, 52 weeks
Change From Baseline in Body Weight at 26 Weeks and 52 Weeks
LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline body weight as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks, 52 weeks
Change From Baseline in Insulin Sensitivity Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks
HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in insulin sensitivity was assessed based on change from baseline of HOMA2-%S using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline HOMA2-%S as a covariate.
Time frame: Baseline, 26 weeks, 52 weeks
Change From Baseline in Beta-cell Function Using Updated Homeostasis Model Assessment (HOMA 2) at 26 Weeks and 52 Weeks
HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in beta-cell function was assessed based on change from baseline of HOMA2-%B using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline HOMA2-%B as a covariate.
Time frame: Baseline, 26 weeks, 52 weeks
Percentage of Participants With Hypoglycemic Episodes
The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least one hypoglycemic episode over the 26-week or 52-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks and Baseline through 52 weeks
30-Day Rate of Hypoglycemic Episodes
The 30-day total hypoglycemia rate over 26 weeks and 52 weeks of treatment is summarized. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks and Baseline through 52 weeks
Number of Participants With Adjudicated Cardiovascular Events at 26 Weeks and 52 Weeks
Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks and Baseline through 52 weeks
Change From Baseline in Pulse Rate at 26 Weeks and 52 Weeks
Sitting pulse rate was measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline pulse rate as a covariate.
Time frame: Baseline, 26 weeks, 52 weeks
Change From Baseline in Blood Pressure at 26 Weeks and 52 Weeks
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline blood pressure as a covariate.
Time frame: Baseline, 26 weeks, 52 weeks
Number of Participants With Adjudicated Pancreatitis at 26 Weeks and 52 Weeks
Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks and Baseline through 52 weeks
Change From Baseline in Pancreatic Enzymes at 26 Weeks and 52 Weeks
Pancreatic enzyme (lipase and total amylase) concentrations were measured.
Time frame: Baseline, 26 weeks, 52 weeks
Change From Baseline in Serum Calcitonin at 26 Weeks and 52 Weeks
Time frame: Baseline, 26 weeks, 52 weeks
Number of Participants With Treatment-Emergent LY2189265 Anti-Drug Antibodies (ADAs) at 26 Weeks and 52 Weeks
A participant was considered to have treatment-emergent LY2189265 ADAs if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from the baseline measurement.
Time frame: Baseline through 26 weeks and Baseline through 52 weeks
Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26 Weeks and 52 Weeks
Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26 and 52 weeks.
Time frame: Baseline through 26 weeks and Baseline through 52 weeks
Change From Baseline in Electrocardiogram Parameters at 26 Weeks and 52 Weeks
Fridericia Corrected QT (QTcF) Interval and PR Interval are summarized. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. LS means were calculated using ANCOVA model with treatment as a fixed effect and the baseline ECG parameter as the covariate.
Time frame: Baseline, 26 weeks, 52 weeks
| Milestone | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| Started | 281 | 70 | 141 |
| Received at least 1 dose of study drug | 280 | 70 | 137 |
| Completed 26 weeks | 271 | 63 | 128 |
| Completed | 263 | 59 | 124 |
| Not completed | 18 | 11 | 17 |
| Withdrew: Adverse event | 6 | 3 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 10 | 6 | 12 |
| Withdrew: Physician decision | 0 | 2 | 1 |
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, prestudy therapy (oral antihyperglycemic medication \[OAM\] yes/no), baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.
| percentage of HbA1c | LY2189265 | Placebo | Liraglutide |
|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks | -1.43 ± 0.05 | 0.14 ± 0.10 | -1.33 ± 0.07 |
LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.
| percentage of HbA1c | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 52 Weeks | -1.39 ± 0.06 | -1.55 ± 0.12 | -1.19 ± 0.08 |
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% at Week 26 and Week 52 was analyzed with a Cochran-Mantel-Haenszel test stratified by prestudy therapy (OAM yes/no) and baseline BMI group (\<25 or \>=25 kg/m\^2).
| percentage of participants | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| HbA1c <7%, 26 weeks | 71.4 | 5.9 | 69.1 |
| HbA1c <=6.5%, 26 weeks | 50.0 | 1.5 | 49.3 |
| HbA1c <7%, 52 weeks | 67.9 | 70.6 | 60.3 |
| HbA1c <=6.5%, 52 weeks | 49.3 | 52.9 | 41.2 |
LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline FBG as a covariate, and participant as a random effect.
| milligrams per deciliter (mg/dL) | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| 26 weeks | -39.18 ± 1.60 | 1.03 ± 3.30 | -39.75 ± 2.27 |
| 52 weeks | -38.93 ± 1.72 | -40.93 ± 3.62 | -37.15 ± 2.47 |
Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal, and at bedtime. LS means were calculated using analysis of covariance (ANCOVA) model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline SMBG as a covariate.
| milligrams per deciliter (mg/dL) | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| Pre-morning meal, 26 weeks | -39.65 ± 1.55 | -0.15 ± 3.04 | -34.93 ± 2.19 |
| 2 hours post-morning meal, 26 weeks | -69.64 ± 2.80 | -9.29 ± 5.48 | -61.67 ± 3.96 |
| Pre-midday meal, 26 weeks | -48.47 ± 2.05 | 3.91 ± 4.03 | -45.08 ± 2.91 |
| 2 hours post-midday meal, 26 weeks | -67.57 ± 2.94 | -1.50 ± 5.77 | -66.71 ± 4.16 |
| Pre-evening meal, 26 weeks | -39.64 ± 2.15 | 9.25 ± 4.22 | -36.62 ± 3.05 |
| 2 hours post-evening meal | -56.70 ± 2.83 | 0.93 ± 5.56 | -53.14 ± 4.01 |
| Bedtime, 26 weeks | -53.39 ± 2.81 | 4.26 ± 5.51 | -51.07 ± 3.94 |
| Pre-morning meal, 52 weeks | -37.46 ± 1.58 | -30.12 ± 3.10 | -33.41 ± 2.23 |
| 2 hours post-morning meal, 52 weeks | -66.96 ± 2.87 | -65.91 ± 5.62 | -60.69 ± 4.06 |
| Pre-midday meal, 52 weeks | -47.03 ± 1.86 | -45.15 ± 3.64 | -46.25 ± 2.63 |
| 2 hours post-midday meal, 52 weeks | -68.21 ± 2.74 | -58.52 ± 5.38 | -62.57 ± 3.88 |
| Pre-evening meal, 52 weeks | -41.04 ± 1.08 | -36.13 ± 3.70 | -32.86 ± 2.67 |
| 2 hours post-evening meal, 52 weeks | -55.01 ± 2.58 | -55.26 ± 5.06 | -42.30 ± 3.65 |
| Bedtime, 52 weeks | -55.76 ± 2.39 | -51.19 ± 4.69 | -49.10 ± 3.35 |
LS means were calculated using MMRM analysis with treatment, visit, treatment-by-visit, prestudy therapy (OAM yes/no), baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects, baseline body weight as a covariate, and participant as a random effect.
| kilograms (kg) | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| 26 weeks | -0.02 ± 0.14 | -0.63 ± 0.29 | -0.36 ± 0.20 |
| 52 weeks | -0.17 ± 0.18 | -1.03 ± 0.37 | -0.13 ± 0.26 |
HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in insulin sensitivity was assessed based on change from baseline of HOMA2-%S using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline HOMA2-%S as a covariate.
| percentage of HOMA2 | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| HOMA2-%S based on FI, 26 weeks (n=254, 57, 115) | -4.83 ± 2.34 | -2.97 ± 4.83 | -4.82 ± 3.43 |
| HOMA2-%S based on FCP, 26 weeks (n=275, 62, 131) | -5.48 ± 1.93 | -6.32 ± 3.99 | -2.46 ± 2.75 |
| HOMA2-%S based on FI, 52 weeks (n=260, 60, 120) | -7.75 ± 2.34 | NA ± NA | -5.26 ± 3.38 |
| HOMA2-%S based on FCP, 52 weeks (n=275, 62, 131) | -11.72 ± 1.88 | NA ± NA | -10.68 ± 2.68 |
HOMA 2 quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Change in beta-cell function was assessed based on change from baseline of HOMA2-%B using fasting insulin (FI) and fasting C-peptide (FCP). LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline HOMA2-%B as a covariate.
| percentage of HOMA2 | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| HHOMA2-%B based on FI, 26 weeks (n=254, 57, 115) | 28.42 ± 1.54 | 0.08 ± 3.14 | 25.35 ± 2.23 |
| HOMA2-%B based on FCP, 26 weeks (n=275, 62, 131) | 27.77 ± 1.27 | 2.94 ± 2.61 | 25.86 ± 1.79 |
| HOMA2-%B based on FI, 52 weeks (n=260, 60, 120) | 27.81 ± 1.39 | NA ± NA | 25.89 ± 1.99 |
| HOMA2-%B based on FCP, 52 weeks (n=275, 62, 131) | 29.59 ± 1.37 | NA ± NA | 28.85 ± 1.93 |
The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least one hypoglycemic episode over the 26-week or 52-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| percentage of participants | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| 26 weeks | 2.1 | 1.4 | 1.5 |
| 52 weeks | 2.9 | 2.9 | 2.9 |
The 30-day total hypoglycemia rate over 26 weeks and 52 weeks of treatment is summarized. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per 30 days | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| 26 weeks | 0.01 ± 0.04 | 0.00 ± 0.02 | 0.00 ± 0.02 |
| 52 weeks | 0.00 ± 0.02 | 0.01 ± 0.09 | 0.01 ± 0.04 |
Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| 26 weeks | 0 | 0 | 0 |
| 52 weeks | 0 | 0 | 0 |
Sitting pulse rate was measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline pulse rate as a covariate.
| beats per minute (bpm) | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| 26 weeks | 3.35 ± 0.45 | 1.49 ± 0.90 | 4.77 ± 0.64 |
| 52 weeks | 3.11 ± 0.42 | 4.42 ± 0.86 | 5.13 ± 0.60 |
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using ANCOVA model with treatment, prestudy therapy (OAM yes/no), and baseline BMI group (\<25 or \>=25 kg/m\^2) as fixed effects and baseline blood pressure as a covariate.
| milliliters of mercury (mmHG) | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| SBP, 26 weeks | 0.62 ± 0.62 | 0.53 ± 1.25 | -2.10 ± 0.89 |
| DBP, 26 weeks | 1.09 ± 0.39 | 0.29 ± 0.78 | 0.43 ± 0.56 |
| SBP, 52 weeks | 1.32 ± 0.66 | 0.37 ± 1.37 | -1.86 ± 0.95 |
| DBP, 52 weeks | 1.41 ± 0.41 | 1.16 ± 0.86 | 1.17 ± 0.60 |
Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| 26 weeks | 0 | 0 | 0 |
| 52 weeks | 0 | 0 | 0 |
Pancreatic enzyme (lipase and total amylase) concentrations were measured.
| units/liter | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| Lipase, 26 weeks | 7.0 (1.0 to 13.0) | 1.0 (-6.0 to 5.0) | 11.0 (5.0 to 21.0) |
| Total Amylase, 26 weeks | 7.0 (2.0 to 15.0) | 0.0 (-6.0 to 6.0) | 7.0 (1.0 to 15.0) |
| Lipase, 52 weeks | 6.0 (1.0 to 12.0) | 6.0 (2.0 to 12.0) | 9.0 (3.0 to 19.0) |
| Total Amylase, 52 weeks | 7.0 (1.0 to 14.0) | 9.0 (3.0 to 14.0) | 6.0 (1.0 to 11.0) |
| picograms/milliliter | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| 26 weeks | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| 52 weeks | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
A participant was considered to have treatment-emergent LY2189265 ADAs if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from the baseline measurement.
| participants | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| 26 weeks (n=279, 68, 133) | 3 | 0 | 0 |
| 52 weeks (n=279, 68, 134) | 3 | 0 | 0 |
Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26 and 52 weeks.
| participants | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| 26 weeks | 0 | 0 | 0 |
| 52 weeks | 0 | 0 | 0 |
Fridericia Corrected QT (QTcF) Interval and PR Interval are summarized. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. LS means were calculated using ANCOVA model with treatment as a fixed effect and the baseline ECG parameter as the covariate.
| milliseconds (msec) | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| QTcF, 26 weeks (n=273, 64, 128) | -2.02 ± 0.70 | -0.96 ± 1.44 | -1.89 ± 1.02 |
| QTcF, 52 weeks (n=274, 64, 128) | -2.76 ± 0.68 | -0.80 ± 1.41 | -4.35 ± 1.00 |
| PR, 26 weeks (n=269, 65, 126) | 2.20 ± 0.60 | -0.45 ± 1.22 | 2.07 ± 0.88 |
| PR, 52 weeks (n=270, 65, 126) | 2.81 ± 0.82 | 2.60 ± 1.33 | 3.71 ± 1.03 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2189265 | — | 9/280 (3.2%) | 182/280 (65%) |
| Placebo/LY2189265 | — | 5/70 (7.1%) | 53/70 (75.7%) |
| Liraglutide | — | 7/137 (5.1%) | 94/137 (68.6%) |
| Event | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 1/15 | 0/24 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/228 | 1/55 | 0/113 |
| Wound infectionInfections and infestations | 0/280 | 1/70 | 0/137 |
| Hand fractureInjury, poisoning and procedural complications | 0/280 | 1/70 | 0/137 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/280 | 1/70 | 0/137 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/280 | 1/70 | 0/137 |
| EosinophiliaBlood and lymphatic system disorders | 0/280 | 0/70 | 1/137 |
| Hiv infectionInfections and infestations | 0/280 | 0/70 | 1/137 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/280 | 0/70 | 1/137 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/280 | 0/70 | 1/137 |
| Event | LY2189265 | Placebo/LY2189265 | Liraglutide |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 52/280 | 7/70 | 24/137 |
| DiarrhoeaGastrointestinal disorders | 20/280 | 6/70 | 6/137 |
| ConstipationGastrointestinal disorders | 22/280 | 4/70 | 11/137 |
| NauseaGastrointestinal disorders | 17/280 | 2/70 | 11/137 |
| HypoaesthesiaNervous system disorders | 2/280 | 5/70 | 1/137 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/52 | 1/15 | 0/24 |
| CystoceleReproductive system and breast disorders | 0/52 | 1/15 | 0/24 |
| RectoceleReproductive system and breast disorders | 0/52 | 1/15 | 0/24 |
| Decreased appetiteMetabolism and nutrition disorders | 2/280 | 2/70 | 8/137 |
| Abdominal distensionGastrointestinal disorders | 12/280 | 0/70 | 7/137 |
Participants who received at least 1 dose of study medication.
| Age, Continuous(years) | LY2189265 | Placebo/LY2189265 | Liraglutide | Total |
|---|---|---|---|---|
| Mean | 57.15 ± 9.57 | 57.66 ± 8.34 | 57.91 ± 10.93 | 57.44 ± 9.63 |
| Sex: Female, Male(Participants) | LY2189265 | Placebo/LY2189265 | Liraglutide | Total |
|---|---|---|---|---|
| Female | 52 | 15 | 24 | 91 |
| Male | 228 | 55 | 113 | 396 |
| Race/Ethnicity, Customized(participants) | LY2189265 | Placebo/LY2189265 | Liraglutide | Total |
|---|---|---|---|---|
| Asian | 280 | 70 | 137 | 487 |
| Region of Enrollment(participants) | LY2189265 | Placebo/LY2189265 | Liraglutide | Total |
|---|---|---|---|---|
| Japan | 280 | 70 | 137 | 487 |
The record gives a start of Mar 2012, a primary completion of Oct 2013 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide